Skip to main content

EMD Millipore First Reseller for Luminex's New Magpix

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Luminex today announced the launch of its new Magpix instrument and said that EMD Millipore is the first value-added reseller of the system worldwide.

The newest offering from Luminex, Magpix offers users the ability to perform up to 50 tests on a single sample and nearly 5,000 data points in under an hour. The low-throughput system, which can analyze both nucleic acids and proteins, is aimed at smaller labs and near-patient settings.

Though it is based on the firm's xMAP technology, it will not use lasers and flow cytometry, which are utilized in its current instrument offerings. It uses lower-cost components, such as light-emitting diodes and a CCD imaging system, and offers a smaller footprint than Luminex's other systems, the Luminex 200 and Flex MAP systems, Luminex President and CEO Patrick Balthrop said at the JPMorgan Healthcare Conference earlier this year.

"This new, highly innovative instrument is an important advancement in our goal to create multiplexing solutions for a range of applications and for laboratories of all sizes," Balthrop said in a statement today.

He noted that EMD Millipore, which was known as Millipore before its recent acquisition by Merck KGaA, has worldwide commercial reach and more than 10 years of experience with the xMAP technology platform.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.